References
- Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol 2009;93:563–568.
- Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2884;82:844–851.
- WHO Alliance for the Global Elimination of Blinding Trachoma by the year 2020. Progress report on elimination of trachoma. Wkly Epidemiol Rec 2013;89:421–428.
- Emerson PM, Lindsay SW, Alexander NB et al. Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. Lancet 2004;363:1093–1098.
- Taylor HR, West SK, Mmbaga BB, et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol 1989;107:1821–1825.
- Thylefors B, Dawson CR, Jones BR, et al. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 1987;65:477–483.
- Mariotti SP, Pararajasegaram R, Resnikoff S. Trachoma: looking forward to Global Elimination of Trachoma by 2020 (GET 2020). Am J Trop Med Hyg 2003;69:33–35.
- World Health Organization. Report of the Third Global Scientific Meeting on Trachoma. Geneva: World Health Organization, 2010.
- Solomon AW, Kurylo E. The global trachoma mapping project. Community Eye Health 2014;27:18.
- Kuper H, Solomon AW, Buchan J, et al. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis 2003;3:372–381.
- Zack R, Mkocha H, Zack E, et al. Issues in defining and measuring facial cleanliness for national trachoma control programs. Trans R Soc Trop Med Hyg 2008;102:426–431.
- Goodhew EB, Priest JW, Moss DM, et al. CT694 and pgp3 as serological tools for monitoring trachoma programs. PLoS Negl Trop Dis 2012;6:e1873.
- Bandea CI, Kubota K, Brown TM, et al. Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect 2001;77:419–422.
- Pavluck A, Chu B, Mann Flueckiger R, et al. Electronic data capture tools for global health programs: evolution of LINKS, an Android-, web-based system. PLoS Negl Trop Dis 2014;8:e2654.
- Burr SE, Hart JD, Edwards T, et al. Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Negl Trop Dis 2013;7:e2347.
- Harding-Esch EM, Sillah A, Edwards T, et al. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Negl Trop Dis 2013;7:e2115.
- Keenan JD, Lakew T, Alemayehu W, et al. Slow resolution of clinically active trachoma following successful mass antibiotic treatments. Arch Ophthalmol 2011;129:512–513.
- Solomon AW, Harding-Esch E, Alexander ND, et al. Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med 2008;358:1870–1871.
- Yohannan J, Munoz B, Mkocha H, et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results. JAMA Ophthalmol 2013;131:431–436.
- Bailey RL, Arullendran P, Whittle HC, et al. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993;342:453–456.
- Goodhew EB, Morgan SM, Switzer AJ, et al. Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration. BMC Infect Dis 2014;14:216.
- Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004;351:1962–1971.
- Bailey R, Duong T, Carpenter R, et al. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect 1999;123:479–486.